Levetiracetam

Generic Name
Levetiracetam
Brand Names
Elepsia, Keppra, Matever, Roweepra, Spritam, Levetiracetam Accord, Levetiracetam Teva, Levetiracetam Actavis, Levetiracetam ratiopharm, Levetiracetam Sun, Levetiracetam Actavis Group, Levetiracetam Hospira
Drug Type
Small Molecule
Chemical Formula
C8H14N2O2
CAS Number
102767-28-2
Unique Ingredient Identifier
44YRR34555
Background

Levetiracetam is a drug within the pyrrolidine class that is used to treat various types of seizures stemming from epileptic disorders. It was first approved for use in the United States in 1999 and is structurally and mechanistically unrelated to other anti-epileptic drugs (AEDs). Levetiracetam possesses a wide therapeutic index and little-to-no potential t...

Indication

Levetiracetam is indicated as an adjunctive therapy in the treatment of partial onset seizures in epileptic patients who are one month of age and older. Additionally, it is indicated as an adjunct in the treatment of myoclonic seizures in patients with juvenile myoclonic epilepsy who are 12 years of age and older, and in primary generalized tonic-clonic seiz...

Associated Conditions
Epilepsies, Generalized Tonic-Clonic Seizures, Partial-Onset Seizures, Myoclonic seizures
Associated Therapies
-
Clinical Trials
Related News

Double-blind, Placebo-controlled Study of Levetiracetam in Adults With POS

Phase 3
Completed
Conditions
Epilepsy, Partial
First Posted Date
2005-09-09
Last Posted Date
2013-12-03
Lead Sponsor
UCB Pharma
Target Recruit Count
192
Registration Number
NCT00152373

Monotherapy With Levetiracetam in Newly Diagnosed Patients Suffering From Epilepsy

Phase 3
Completed
Conditions
Generalized Epilepsy
First Posted Date
2005-09-08
Last Posted Date
2013-11-26
Lead Sponsor
UCB Pharma
Target Recruit Count
580
Registration Number
NCT00150735

A Study Of The Safety And Efficacy Of Levetiracetam (Keppra®) (Ucb L059) In Children With Epilepsy

Phase 3
Completed
Conditions
Epilepsy, Partial
Interventions
Drug: Levetiracetam
First Posted Date
2005-09-08
Last Posted Date
2024-02-09
Lead Sponsor
UCB Pharma
Target Recruit Count
223
Registration Number
NCT00150709

Monotherapy With Levetiracetam in Patients Suffering From Epilepsy.

Phase 3
Completed
Conditions
Epilepsy, Tonic-clonic
Interventions
Drug: Levetiracetam
First Posted Date
2005-09-08
Last Posted Date
2018-11-21
Lead Sponsor
UCB Pharma SA
Target Recruit Count
66
Registration Number
NCT00150813

Levetiracetam as add-on Treatment of Myoclonic Jerks in Adolescents + Adults

Phase 3
Completed
Conditions
Generalized Convulsive Epilepsy
First Posted Date
2005-09-08
Last Posted Date
2013-09-17
Lead Sponsor
UCB Pharma
Target Recruit Count
116
Registration Number
NCT00150774

Monotherapy With Levetiracetam or Carbamazepine in Patients Suffering From Epilepsy.

Phase 3
Completed
Conditions
Epilepsy, Tonic-clonic
First Posted Date
2005-09-08
Last Posted Date
2013-11-26
Lead Sponsor
UCB Pharma
Target Recruit Count
250
Registration Number
NCT00150787

Efficacy and Safety of Levetiracetam in the Inpatient Treatment of Alcohol Withdrawal Syndrome

First Posted Date
2005-09-07
Last Posted Date
2009-12-30
Lead Sponsor
Charite University, Berlin, Germany
Target Recruit Count
120
Registration Number
NCT00146471
Locations
🇩🇪

Klinik für Psychiatrie und Suchtmedizin, Kliniken Essen Mitte, Essen, Germany

🇩🇪

Charité - Universitätsmedizin Berlin, Campus Charité Mitte, Klinik für Psychiatrie und Psychotherapie, Berlin, Germany

🇩🇪

Zentrum für Seelische Gesundheit, Rhede, Germany

and more 2 locations

Levetiracetam for the Treatment of Alcohol Dependence and Anxiety

First Posted Date
2005-09-01
Last Posted Date
2019-04-24
Lead Sponsor
New York State Psychiatric Institute
Target Recruit Count
3
Registration Number
NCT00141115
Locations
🇺🇸

New York State Psychiatric Institute, New York, New York, United States

A 19-week Cognition Study of Levetiracetam in Children With Partial Onset Seizures

Phase 2
Completed
Conditions
Epilepsy, Partial
Interventions
Other: Placebo (PB)
Drug: Levetiracetam
First Posted Date
2005-03-04
Last Posted Date
2015-03-02
Lead Sponsor
UCB Pharma
Target Recruit Count
87
Registration Number
NCT00105040

Pilot Study of Levetiracetam (Keppra® (Registered Trademark)) for Bipolar Illness

Phase 2
Completed
Conditions
Bipolar Disorder
First Posted Date
2001-05-07
Last Posted Date
2008-03-04
Lead Sponsor
National Institute of Mental Health (NIMH)
Target Recruit Count
30
Registration Number
NCT00015769
Locations
🇺🇸

National Institute of Mental Health (NIMH), Bethesda, Maryland, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy